Study Evaluating the Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV).

These illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when they are not necessary in many cases.

However, the excessive use of antibiotics contributes to the development of bacterial resistance, which is a major public health issue.

The aim of this study is to better understand whether the use of a rapid test (called TROD), which can quickly identify certain respiratory viruses, can help doctors reduce unnecessary antibiotic prescriptions for these infections. The test will be performed using a swab gently inserted into the nose.

Eligibility criteria

Qualifiers

Age ≥ 1 year

Rhinorrhea (white, yellow, or green discharge) and/or nasal obstruction, and cough

Body aches, cough, and fatigue

Odynophagia and negative strepto-test

Disqualifiers

Requirement for hospitalization

Presence of a non-respiratory infection requiring concomitant antibiotic treatment.

Patients covered by State Medical Aid (AME)

Trial design

Treatments tested in this trial

  • TROD

Treatment groups

2,000 Participants
are divided into 2 treatment groups